Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients
Glenn M. Chertow(Stanford Health Care), for the Treat to Goal Working Group, Paolo Raggi(University of Alberta), Steven K. Burke(Akebia Therapeutics (United States))
Cited by 1,459
Related Papers
Chronic Kidney Disease and the Risks of Death, Cardiovascular Events, and Hospitalization
|New England Journal of Medicine|2004|11.4k
Dapagliflozin in Patients with Chronic Kidney Disease
|New England Journal of Medicine|2020|5.2k
Acute Kidney Injury, Mortality, Length of Stay, and Costs in Hospitalized Patients
|Journal of the American Society of Nephrology|2005|3.4k
Mineral Metabolism, Mortality, and Morbidity in Maintenance Hemodialysis
|Journal of the American Society of Nephrology|2004|2.7k
From Vulnerable Plaque to Vulnerable Patient
|Circulation|2003|2.7k